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A B S T R A C T
CThe objective of the present study was to prepare solid self-nanoemulsifying drug delivery
system (S-SNEDDS) containing Capryol-90 as oil phase for the delivery of Embelin, a poorly
water soluble herbal active ingredient. Box-Behnken experimental design was employed to
optimise the formulation variables, X1 (amount of oil; Capryol 90), X2 (amount of surfac-
tant; Acrysol EL 135) and X3 (amount of co-surfactant; PEG 400). Systems were appraised for
visual characteristics for self emulsifying time, globule size and drug release.Optimised liquid
formulations were formulated into free flowing granules (S-SNEDDS) by adsorption on the
porous materials like Aerosil 200 and Neusilin and thereby compressed into tablet. In vitro
dissolution studies of SNEDDS revealed increased in the dissolution rate of the drug. FT-IR
data revealed no physicochemical interaction between drug and excipients. Solid state char-
acterization of S-SNEDDS by DSC and Powder XRD confirmed reduction in drug crystallinity
which further supports the results of dissolution studies. TEM analysis exhibited spherical
globules. Further, the accelerated stability studies for 6 months revealed that S-SNEDDS of
Embelin are found to be stable without any significant change in physicochemical proper-
ties. Thus, the present studies demonstrated dissolution enhancement potential of porous
carrier based S-SNEDDS for poorly water soluble herbal active ingredient, Embelin.
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Embelin, (EMN) a benzoquinone found in Vidanga, is poorly
water soluble drug which possess wide range of medicinal prop-
erties. Embelin exhibits antibacterial, antifertility and
antioxidant properties [1–3]. EMN plays an important role in
diabetes by counteracting high levels of glucose in the blood
[4]. EMN demonstrates cytotoxic effect and inhibits cell pro-
liferation in various cancer cell types [5]. However, the
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bioavailability of EMN is extremely erratic due to inherent poor
aqueous solubility and dissolution properties [6].With the ob-
jective of improving the poor solubility and dissolution
properties of drug, advanced drug delivery systems are requisite.
Oral bioavailability of poorly water soluble drugs may be en-
hanced if formulated with lipids. One of the accepted
approaches is the exploitation of lipid and surfactant based
drug delivery systems (SNEDDS) [7]. SNEDDS are the isotro-
pic mixtures of drug, lipid and surfactants, usually with one
or more hydrophilic co-solvents or co-emulsifiers which upon
mild agitation generates ultrafine droplets of oil in water
nanoemulsion [8].The free energy required for self nano emul-
sification process is low. Thus, the process will occur
spontaneously [9]. The enhanced interfacial area of micron-
ized globules will facilitate the dissolution of drug thereby
improving the bioavailability and enhance permeability through
biological membranes due to presence of lipid and surfac-
tant [10]. Therefore, solid SNEDDS is highly coveted due to its
scalability and lustiness along with all advantages of liquid
system.
Therefore, in light of this, the present investigation was
carried out to improve dissolution characteristics of EMN by
preparing SNEDDS. Box Behnken Design was applied to opti-
mize SNEDDS containing EMN. Box Behnken Design is an
independent, rotatable, or nearly rotatable quadratic design
(contains no embedded factorial or fractional factorial design),
in which the treatment points are the end of the edges of the
process space and at the centre [11]. Among all the Response
surface methodology designs, Box-Behnken design requires
fewer runs (13 runs) in a 3-factor experimental design [12].
Hence, the Box-Behnken Design was applied to optimize EMN-
SNEDDS. Independent variables (factors) selected were amount
of oil (Capryol 90) (X1), amount of surfactant (Acrysol EL 135)
(X2) and amount of co-surfactant (PEG 400) (X3). The de-
pended variables included globule size in nanometer (Y1) and
self emulsification time in sec (Y2). To optimise EMN SNEDDS,
mathematical model equations were derived by computer simu-
lation programming Design Expert 8.0.5 software (State-Ease
Inc. Mineapolis, USA). Physicochemical characterization was
done by Fourier Transform Infrared Spectroscopy, Differential
Scanning Calorimetry and Powder X-Ray Diffraction studies.
To understand the morphology, diluted SNEDDS of EMN were
subjected to Transmission Electron Microscopy studies.
2. Materials and methods
2.1. Materials
EMN was a gift sample from BR Nahta College of Pharmacy,
Mandsaur, India. Capryol 90, Labrafil and Paceol were gifted from
Gattefosse, Mumbai, India. Oleic acid and Isopropyl myristate
were purchased from Loba Chemie, Mumbai, India. Acrysol EL
135 and Acrysol K 140 were gift sample from Corel Pharma,
Ahmedabad, India. Gelucire 44/14 was provided from Gatteffose
India Pvt Ltd, Mumbai, India. Labrasol and Cremophore RH 40
were gifted from BASF, Mumbai, India. PEG 200, PEG 400 and
Propylene glycol were purchased from Hi Media Labs, Mumbai,
India.Aerosil 200 and Neusilin US2 were obtained from Gangwal
Chemicals Ltd, Mumbai, India. All other ingredients used were
of analytical grade.
2.2. Solubility studies
Solubility studies were conducted by adding an excess amount
of EMN to 2 ml of oils, surfactants or co-surfactants. The mix-
tures were then swirled and sonicated for 30 min, respectively,
followed by shaking at 37 °C for 48 h usingWater Bath Shaker
(Remi, Mumbai, India). The mixtures were kept at room tem-
perature for 24 h and centrifuged using 12C-micro centrifuge
(Remi, Mumbai, India) at 3000 rpm for 15 min. The separated
supernatant fraction was suitably diluted with methanol and
analysed for drug concentration spectrophotometrically at λmax
291 nm using UV-Visible spectrophotometer (Shimadzu 1800,
Japan).
2.3. Construction of ternary phase diagram
Various mixtures with varying concentration of surfactant, co-
surfactant and oil were prepared. Ternary diagrams of
surfactant, co-surfactant and oil were plotted.The levels of sur-
factant, co-surfactant and oil were varied from 40 % to 90 %
(w/w), 0% to 30 % (w/w) and 10 %–60 % (w/w), respectively. All
compositions were examined for nanoemulsion formation after
diluting each of the mixtures 200 times with distilled water.
Thereafter, transmittance and globule size of the resulting dis-
persions were measured using UV-Visible Spectrophotometer
(Shimadzu 1800, Japan) at 650 nm and Particle size analyser
(Malvern Instruments, UK) respectively. Dispersions having
globule size 200 nm or below were considered acceptable.
2.4. Formulation and optimization of SNEDDS using Box-
Behnken design
Three factors, three level (33) and 13 runs Box-Behnken Ex-
perimental Design using Design Expert 8.0.5 software (State-
Ease Inc. Mineapolis, USA) was employed to formulate liquid
SNEDDS. The concentration of Capryol 90 (X1), Acrysol EL 135
(X2) and PEG 400 (X3) were selected as independent vari-
ables, while globule size in nanometer (Y1) and self
emulsification time in sec (Y2) were selected as responses. Re-
sponse surface analysis was carried out to study the effect of
different independent variables on the observed responses.The
independent and dependent variables are listed in Table 1.
Weighed quantity of EMN (100 mg) was mixed with oil, sur-
factant and co-surfactant with continuous stirring to obtain
a homogeneous mixture. The prepared liquid SNEDDS
were stored in sealed transparent glass bottles at room
Table 1 – Factors investigated using Box-Behnken
experimental design.
Independent variables Levels (mg)
Low Medium High
X1 = Amount of oil (Capryol 90) 49.50 57.75 66.00
X2 = Amount of surfactant
(Acrysol EL 135)
99.00 107.25 115.50
X3 = Amount of co-surfactant (PEG 400) 16.5 24.75 33.00
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temperature until used. The formulations were recorded for
any changes in turbidity or phase separation.
2.5. Characterization of SNEDDS
2.5.1. Dispersibility studies
Self emulsification time was assessed by dispersibility studies.
One ml of SNEDDS was added drop wise to 500 ml of 0.1N HCl
with gentle agitation using USPType II (paddle) dissolution ap-
paratus rotating at 50 rpm at temperature 37 ± 0.5 °C. The
process of self emulsification was visually monitored. Precipi-
tation was assessed by visual monitoring of the resultant
emulsion after 24 h storage at room temperature.
2.5.2. Globule size, size distribution and zeta potential
Malvern Zetasizer (Malvern Instruments, UK) was employed
to determine globule size, polydispersity index and zeta po-
tential. Liquid SNEDDS or Solid SNEDDS were diluted 1000 times
with distilled water and shaken gently to form a fine emul-
sion and the resultant emulsion was utilised for the further
study. The values of z-average diameters were used.
2.5.3. Comparative in vitro drug release studies
In vitro drug release studies of EMN drug loaded liquid SNEDDS,
Solid-SNEDDS, Formulation based tablet and pure drug were
carried out in USP type II dissolution apparatus (Model Disso
2000, Lab India) using 900 ml of phosphate buffer (pH 7.4) as
dissolution media, at 50 rpm and temperature 37 ± 0.5 °C.
Aliquots of 5 ml was withdrawn at suitable time interval (5,
10, 15, 20, 30 45, 60 and 90 min), filtered, appropriately diluted
and analysed spectrophotometrically at λmax of 291 nm by UV/
Visible spectrophotometer (UV-1800 Shimadzu, Japan).
2.5.4. Refractive index measurement
The optical clarity of the optimized liquid SNEDDS formula-
tion was determined in terms of refractive index using Abbe’s
refractrometer (Mettler Toledo, Mumbai, India).
2.5.5. Transmission electron microscopy
For visual observation optimized batch of SNEDDS was sub-
jected to transmission electron microscopy (TEM) (H-7000,
Hitachi, Japan). Briefly, a drop of diluted SNEDDS was placed
on a copper grid stained with 1% w/v phosphotungistic acid
solution for 5 min at room temperature. The image was taken
with transmission electronmicroscope at an accelerated voltage
of 100 kV.
2.6. Preparation of Solid-SNEDDS
The optimised liquid SNEDDS formulation was transformed into
solid free flowing granules using Neusilin US2 and Aerosil 200
as adsorbent material. Appropriate quantities of adsorbent ma-
terials required to convert a given amount of liquid SNEDDS
into an acceptably flowing and compressible system were de-
termined.The solid formulations obtained were passed through
sieve number 22 to achieve uniformly free flowing self
nanoemulsifying granules (SNEG’s). The final blend of opti-
mized batch obtained was compressed into tablet using Rotary
tablet compression machine (Hardik, Tablet Press, Ahmed-
abad, India); flat faced and die sized 9 mm punch were used.
For comparison other tablets were prepared by directly com-
pressing powder mixture of EMNwith Neusilin US2,Aerosil 200
and sodium starch glycolate.
2.7. Characterization of Solid-SNEDDS
The prepared S-SNEDDS were evaluated for various
micromeritic properties viz. Bulk density, tapped density, angle
of repose, Carr’s Index and Hausner’s ratio. In vitro drug release
studies of S-SNEDDS and the tablet prepared were deter-
mined using dissolution studies.
2.7.1. Drug content estimation
Liquid SNEDDS, S-SNEDDS and tablet containing EMN, each
equivalent to 100 mg of drug was dispersed into appropriate
quantity of methanol, stirred sufficiently to dissolve the drug,
and centrifuged at 3000 rpm for 15 min. The supernatant was
duly diluted and analysed spectrophotometrically at λmax of
291 nm by UV/visible spectrophotometer (UV-1800 Shimadzu,
Japan).
2.7.2. Fourier transformed infrared spectroscopy
Fourier transformed infrared spectroscopy (FT-IR) of pure drug,
optimized Solid-SNEDDS, Physical mixture and blank Solid-
SNEDDS were carried out using KBr disc. The spectra were
recorded using Fourier transform infrared spectrophotom-
eter (Shimadzu 8400, Japan). Each KBr disc was scanned at
4 mm/s at a resolution of 2 cm over a wave number region of
4000–400 cm−1. An average of 20 scans was taken.
2.7.3. Differential scanning calorimetry studies
Thermal analysis of final formulation of pure drug, opti-
mized Solid-SNEDDS, Physical mixture and blank Solid-
SNEDDS were carried out using Differential scanning
calorimeter (DSC) (Shimadzu, DSC 60TSW 60, Japan). Study was
carried out between the range of 50–200 °C, at a scanning rate
of 10 °C/min. An empty pan was used as a reference.
2.7.4. Powder X-ray diffraction studies (PXRD)
To observe crystallographic pattern of pure drug, optimized
Solid-SNEDDS, Physical mixture and blank Solid-SNEDDS were
carried out using Powder X-ray diffractometer (Phillips X-Pert
MPD, The Netherlands) using a voltage of 45 kV, generator
current 40mA, scan step time 9 sec−1 and scan step size of 0.008°
(2θ). The scanning rate employed was maintained over the in-
terval 1–50° 2θ−1.
2.7.5. Accelerated stability studies
The optimised S-SNEDDS based tablets were stored at 40°±5 °C/
75 ± 5% RH for 6 months. Samples were withdrawn at definite
time interval (0, 1, 2, 3 and 6 months) and analysed for self
emulsification time, globule size and drug release at 15 min.
3. Results and discussion
3.1. Solubility studies
Comparative study of solubility of EMN in various liquids is
given in the Table 2. Solubility was found to be highest in
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Capryol 90, Acrysol EL 135 and PEG 400 among the oils, sur-
factants and co-surfactants respectively. They were further
utilized for the construction of ternary phase diagram.
3.2. Construction of ternary phase diagrams
Fig. 1 depicts the phase diagram of the systems containing
Capryol 90 as oil, Acrysol EL 135 as surfactant and PEG 400 as
co-surfactant. The ternary phase diagrams were constructed
to determine the concentration range of components for the
formation of nanoemulsion. All the components were con-
verted into weight/weight percent before construction of the
phase diagram. The darker region in the phase diagram rep-
resents the self emulsification area. It was observed that the
efficiency of emulsification was improved by the aid of
Table 2 – Solubility studies of EMN in various solvents.
Solvents Solubility (mg/gm)
Oils Capryol 90 399.41 ± 3.79
Labrafil 77.78 ± 8.19
Paceol 188.61 ± 4.49
Oleic acid 77.91 ± 9.66
Isopropyl myristate 140.93 ± 6.72
Surfactants Acrysol EL 135 256.37 ± 1.31
Acrysol K 140 242.88 ± 3.05
Gelucire 44/14 101.20 ± 5.29
Cremophore RH 40 202.77 ± 1.59
Labrasol 37.86 ± 2.36
Co-surfactants PEG 400 149.89 ± 1.19
PEG 200 133.51 ± 2.35
Propylene glycol 103.82 ± 2.17
Fig. 1 – Ternary phase diagram of Capryol 90, Acrysol EL
135 and PEG 400.
Table 3 – Box-Behnken experimental design with
measured responses.
Batch no. X1 X2 X3 Y1 (nm) Y2 (sec)
E1 −1 −1 0 40.47 ± 2.59 27.86 ± 3.79
E2 1 −1 0 88.21 ± 2.95 113.38 ± 4.13
E3 −1 1 0 35.59 ± 3.59 22.56 ± 3.09
E4 1 1 0 71.35 ± 1.49 85.75 ± 2.11
E5 −1 0 −1 58.58 ± 2.88 39.78 ± 1.53
E6 1 0 −1 99.35 ± 1.33 127.43 ± 3.02
E7 −1 0 1 32.31 ± 1.32 20.68 ± 2.49
E8 1 0 1 80.45 ± 4.00 83.42 ± 2.85
E9 0 −1 −1 69.16 ± 1.51 75.38 ± 4.08
E10 0 1 −1 62.21 ± 0.77 70.46 ± 3.01
E11 0 −1 1 55.78 ± 1.57 58.49 ± 5.63
E12 0 1 1 28.85 ± 1.82 37.76 ± 4.28
E13 0 0 0 38.46 ± 1.08 52.23 ± 4.18
Fig. 2 – Response surface plot (a) interaction between X1
and X2 onY1 (b) interaction between X1 and X3 onY2 (c)
overlay plot.
399a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 9 6 – 4 0 4
surfactant-cosurfactant addition due to their higher hydro-
philicity properties [13]. Stable systems were observed with
concentration of oil upto 45% w/w in the system. It was ob-
served that addition of co-surfactant, PEG 400 improved the
self emulsification property of the system [14]. It was ob-
served that spontaneous emulsion formation was not efficient
with less than 45% w/w of the surfactant in the system.
3.3. Optimization of SNEDDS
A Box-Behnken experimental design with 3 independent vari-
ables at 3 different levels was used to study the effect on
dependent variables. A total of 13 formulations were pre-
pared as per the experimental design and characterized further
for responses like globule size and self emulsification time as
shown in Table 3. For all the 13 batches dependent variables,
globule size (Y1) and self emulsification time (Y2) demon-
strated wide variations from 28.85 ± 1.82 to 99.35 ± 1.33 nm
and 20.68 ± 2.49 to 113.38 ± 4.13 s respectively indicating good
influence of independent variables (X1, X2 and X3) on the se-
lected responses.
The relationship between the dependent and indepen-
dent variables was further enlightened using response surface
plot shown in Fig. 2. The mathematical relationships were es-
tablished and coefficients of second order polynomial equation
generated using multi linear regression analysis for globule size
and self emulsification time. The equations were found to be
quadratic in nature with interaction terms.The coefficients of
the polynomials fitted well to the data, with the values of R2,
0.9964 and 0.9978 for Y1 and Y2 respectively.
Y b b X b X b X b X X b X X
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Fig. 2a depicts an interaction effect between oil (Capryol 90)
and surfactant (Acrysol EL 135) on the globule size as depen-
dent variable. With increasing the amount of Capryol 90 and
Acrysol EL 135, a linear increase in the globule size was ob-
served. Fig. 2b shows the response surface plot, characterizing
increase in the SEF with increase in the concentration of oil
(Capryol 90) and co-surfactant (PEG 400). All the response sur-
faces were fitted with quadratic polynomial models.TheANOVA
results are shown in Table 4. The F calculated value 4.16 and
3.38 is less than the table value 9.55 for Y1 and Y2, respec-
tively. Hence it is concluded that the omitted terms do not
significantly contribute in predicting globule size and self emul-
sification time.
Using software optimisation process and response surface
plots shown in Fig. 2c, level selected for X1, X2 and X3 were
49.50, 115.50 and 24.75 respectively, which gives theoretical
values of 33.39 nm and 23.26 s for globule size and self emul-
sification time respectively. Fresh formulation was prepared
using the optimum levels of independent variables. The ob-
served values of globule size and self emulsification time were
found to be 30.15 ± 2.68 nm and 21.62 ± 1.19 s, respectively,
which were in close agreement with the theoretical values.
3.4. Characterization of SNEDDS
Table 3 summarised mean globule size and self emulsifica-
tion time of prepared SNEDDS (E1-E13).The largest droplet size
appeared in E6 of 99.35 ± 1.33 nm which could be due to pres-
ence of high amount of oil and lesser amount of surfactant-
co-surfactant mixture [15]. All the liquid formulations showed
good self emulsification efficiency forming nanoemulsion im-
mediately after dilution. In vitro drug release study data as
shown in Fig. 3, revealed dissolution enhancement with more
Table 4 – Results of ANNOVA.
Response Y1 Df (2,3) SS MS F P value
Regression Ftab = 9.55
FM 9 6127.33 680.81 91.23 0.0017
RM 7 6065.24 866.46 51.28 0.0002
Error Fcal = 4.16
FM 3 22.39 7.46
RM 5 84.48 16.90
Response Y2 Df (2,3) SS MS F P value
Regression Ftab = 9.55
FM 9 13,775.63 1530.63 153.95 0.0008
RM 7 13,708.49 1958.36 100.98 <0.0001
Error Fcal = 3.38
FM 3 29.83 9.94
RM 5 96.97 19.39
Fig. 3 – In vitro release study of EMN and EMN loaded
SNEDDS (E1-E13).
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than 80% drug release in initial 15 min while pure drug release
was found to be 5.7 ± 0.30% within 15 min.This suggested that
dissolution enhancement of pure drug in formulation might
be imputed to solubility enhancement property of selected ex-
cipients [16].
Zeta potential values of E1 to E13 as depicted in Table 5 were
found in the range of −31.47 ± 1.76 mV to −26.02 ± 1.53 mV.
Optimised formulation had zeta potential value of
−28.69 ± 1.67 mV. Zeta potential values in the range of −25 mV
to −30 mV in either charge signifies a stable formulation [17].
Polydispersity index is the measure of globule size homoge-
neity.Value closer to zero,more homogeneous are the particles.
Refractive index (RI) values of SNEDDS were found to be in the
range of 1.35 ± 0.03 to 1.57 ± 0.02. RI of optimized batch was
found to be 1.38 ± 0.03. PI and RI values are shown in Table 5.
TEM image of the optimized SNEDDS after dilution appeared
as dark globules as depicted in Fig. 4.
3.5. Characterization of Solid-SNEDDS
The drug loaded S-SNEDDS were prepared choosing optimised
batch as per the composition illustrated in Table 6.Tablets were
prepared using 5% w/w Sodium starch glycolate as
superdisintegrant. Results of micromeritic properties indi-
cate good flow property of the formulation with values of angle
of repose; 25.5, Carr’s Index; 20.5 and Hausner’s ratio; 1.15.The
In-vitro dissolution studies revealed faster drug release prop-
erty with 99.60 ± 0.85% of drug release within 15 min.
The tablet hardness was found to be 5 kg/cm2, disintegra-
tion time less than 3 min and friability less than 1%.
3.5.1. Comparative in-vitro drug release studies
In vitro drug release studies of pure drug, optimised liquid
SNEDDS, S-SNEDDS and prepared tablet were carried out using
dissolution studies as shown in Fig. 5. The drug release dem-
onstrated optimized liquid SNEDDS, S-SNEDDS and prepared
tablet exhibited faster drug release within 15 min up to
99.60 ± 0.85%, 97.80 ± 1.27% and 96.45 ± 1.91% respectively, in
comparison to 5.7 ± 0.30% of pure drug.The faster drug release
from liquid SNEDDS might be attributed to spontaneous
nanoemulsion formation [18]. Drug release from S-SNEDDS was
slightly lower than liquid SNEDDS, it might be attributed to the
presence of adsorbent materials while that for tablet, addi-
tional process of disintegration of tablet into granules and then
desorption of liquid SNEDDS from excipients surface might be
the reason.
3.5.2. Fourier transformed infrared (FT-IR) spectroscopy
The FT-IR spectra, Fig. 6 (a) of drug showed bands at 3398 (-OH),
3001 (-CH) and 1776 (C=O) cm−1. Drug loaded S-SNEDDS system
Table 5 – Values of polydispersity index, refractive index
and zeta potential.
Batches PI RI Ζ (mV)
E1 0.17 ± 0.01 1.45 ± 0.03 −28.52 ± 1.88
E2 0.22 ± 0.02 1.36 ± 0.02 −30.07 ± 2.02
E3 0.21 ± 0.03 1.47 ± 0.01 −31.47 ± 1.76
E4 0.18 ± 0.03 1.35 ± 0.03 −28.21 ± 1.51
E5 0.17 ± 0.02 1.48 ± 0.03 −27.26 ± 2.58
E6 0.22 ± 0.02 1.52 ± 0.03 −29.04 ± 1.56
E7 0.19 ± 0.02 1.56 ± 0.04 −29.20 ± 1.59
E8 0.22 ± 0.03 1.38 ± 0.06 −29.50 ± 2.62
E9 0.23 ± 0.04 1.41 ± 0.04 −29.52 ± 1.39
E10 0.18 ± 0.02 1.48 ± 0.03 −26.02 ± 1.53
E11 0.16 ± 0.02 1.57 ± 0.02 −27.67 ± 1.41
E12 0.21 ± 0.01 1.47 ± 0.04 −27.05 ± 1.76
E13 0.15 ± 0.02 1.49 ± 0.05 −26.83 ± 0.92
Fig. 4 – Transmission electron microscopy of Optimized
EMN-SNEDDS.
Table 6 – Composition of optimised batch.




Neusilin US2 (carrier) 437.39 51.46
Aerosil 200 (coating agent) 43.74 5.15
Sodium starch glycolate 42.50 5.00
Lactose monohydrate 30.68 3.61
Fig. 5 – In vitro drug release study of Optimized Liquid
SNEDDS, S-SNEDDS and S-SNEDDS Tablet.
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Fig. 6 (b) showed no specific physicochemical interaction. It was
observed that all important peaks due to functional group of
drug were presented in physical mixture, Fig. 6 (c). There was
no significant difference found in wave number (cm−1) of the
drug, broadening effect was observed [19].
3.5.3. Differential scanning calorimetry studies
Fig. 7 shows DSC thermograms of pure EMN (a), optimized
S-SNEDDS (b), Physical mixture (c) and blank S-SNEDDS (d).The
thermogram of EMN showed a single endothermic peak at
149 °C, whereas thermogram of S-SNEDDS showed
dissappearance of characteristic peak of EMN, supporting mo-
lecular dispersion of drug in excipients and conversion of
crystalline form into amorphous form [20]. Physical mixture
showed retention of characteristic peak of EMN.
3.5.4. Powder X-ray diffraction studies (PXRD)
The PXRD of EMN in Fig. 8(a) showed sharp peaks at 13.3°, 16.2°,
19.0°, 21.6°, 23.5° and 25.3° demonstrating its crystalline nature
whereas spectra of optimized S-SNEDDS Fig. 8(b) showed dis-
appearance of sharp peaks of EMN indicating conversion into
amorphous form [21,22]. Physical mixture, Fig. 8(c) showed sharp
peaks of ELN at 13.3°, 19.0° and 21.6°. Amorphous halo peaks
were observed in the diffractogram of blank S-SNEDDS with
a peak at 21.8° corresponding to peak of PEG 400.
3.5.5. Accelerated stability studies
Results of different parameters like self emulsification time,
globule size and drug release of optimized S-SNEDDS based
tablet were evaluated at specific intervals (0, 1, 2, 3 and 6
months) are depicted in Table 7. Results showed that there was
no significant change in these parameters.
4. Conclusion
In the present investigation, SNEDDS formulation was pro-
posed to enhance the dissolution properties of poorly water
soluble herbal active ingredient, EMN. Liquid SNEDDS were
transformed into S-SNEDDS by adsorbing onto adsorbents,
Aerosil 200 and Neusilin US2. The drug release studies re-
vealed higher and uniform release of EMN from the
formulations. DSC and PXRD studies indicated incorporation
of drug into SNEDDS components. EMN SNEDDS were found
to be chemically and physically stable for 6 months. Thus, it
can be inferred that physicochemically stable EMN SNEDDS
Fig. 6 – FT-IR spectra of (a) EMN and (b) Optimized S-SNEDDS (c) Physical mixture (d) Blank S-SNEDDS.
Table 7 – Characterization of optimised S-SNEDDS based










drug at 15 min
0 23.53 ± 1.38 30.37 ± 1.56 97.33 ± 0.89
1 23.22 ± 1.53 28.18 ± 1.18 97.99 ± 1.60
2 22.84 ± 0.58 29.48 ± 2.02 96.97 ± 1.71
3 23.19 ± 1.18 30.63 ± 0.59 96.43 ± 1.13
6 22.98 ± 1.08 30.22 ± 1.26 97.06 ± 0.91
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Fig. 7 – DSC spectra of (a) EMN and (b) Optimized S-SNEDDS (c) Physical mixture (d) Blank S-SNEDDS.
Fig. 8 – PXRD spectra of (a) EMN and (b) Optimized S-SNEDDS (c) Physical mixture (d) Blank S-SNEDDS.
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have potential to enhance the dissolution properties of poorly
water soluble drug, EMN.
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